Experimental combo for tough lung cancer shows early promise, but study halted
NCT ID NCT06016270
First seen Jun 24, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase trial tested an experimental antibody called hSTC810 combined with the chemotherapy drug paclitaxel in 10 adults with relapsed or refractory extensive-stage small cell lung cancer. The goal was to see if the combination is safe and helps shrink tumors or slow the cancer's growth. However, the study was terminated early, so we have very limited information about how well it worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- hSTC810 (an experimental antibody) combined with paclitaxel (a chemotherapy drug)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with relapsed small cell lung cancer, potentially slowing disease progression.
- What could go wrong
- The trial was terminated early with only 10 participants, so results are very limited. It is unclear if the combination is safe or effective, and side effects from chemotherapy are common.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EXTENSIVE-STAGE SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
-
Korea University Anam Hospital
Seoul, 02841, South Korea
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Samsung Medical Center
Seoul, 06351, South Korea
-
Seoul National University Bundang Hospital
Seoul, 13620, South Korea
-
Seoul National University Hospital
Seoul, 03080, South Korea
-
The Catholic University of Korea St. Vincent's Hospital
Suwon, 16247, South Korea
-
Tisch Cancer Institute at Mount Sinai
New York, New York, 10029, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink tough lung cancers?
- Can a smartphone app ease the burden of advanced lung cancer?
- Cholesterol-Lowering drug may boost lung cancer immunotherapy
- Lung cancer drug tislelizumab under Real-World scrutiny in 440-Patient european study
- New combo shows promise for tough lung cancer
- New hope for tough lung cancer: combo therapy enters phase II trial